The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnanda Developments Plc Regulatory News (ANA.PL)

Share Price Information for Ananda Developments Plc (ANA.PL)

Aquis Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.315
Bid: 0.28
Ask: 0.35
Change: 0.00 (0.00%)
Spread: 0.07 (25.00%)
Open: 0.315
High: 0.315
Low: 0.315
Prev. Close: 0.315
ANA.PL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Audit & Notice of AGM

31 Jul 2023 17:44

RNS Number : 8031H
Ananda Developments PLC
31 July 2023
 

31 July 2023

 

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

 

Completion of Audit, Publication of Annual Report and Accounts and Notice of Annual General Meeting

 

Further to the announcement of its 2022/23 unaudited preliminary results on 13 July 2023, Ananda announces that the audit for the year ended 31 January 2023 has now been completed. Adjustments have been made to the previously notified Consolidated Statement of Cashflows and Balance Sheet, which are reflective of adjustments made a part of a review of the acquisition of DJT Group Limited, revised tables are set out below.

 

The Company's Annual Report and Accounts for the year ended 31 January 2023, together with a Notice of Annual General Meeting, has been published on the Company's website. The notice of Annual General Meeting have also today been posted to, or emailed to, shareholders as appropriate in accordance with the provision in the Company's articles of association on electronic communications.

 

The Annual General Meeting is due to be held at the offices of Shakespeare Martineau Llp, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR at 2.00pm on 24th August 2023.

 

 

Statement of Financial Position

 

GROUP

 

31 Jan 2023

 

31 Jan 2022

Note

£

£

Non-Current assets

 

Tangible Assets

10

1,762,468

-

Intangible Assets

12

4,470,376

-

Investments in subsidiaries

-

2,252,192

Total non-current assets

6,232,844

2,252,192

 

 

Current assets

Cash and cash equivalents

18,837

-

Assets under construction

47,080

-

Trade and other receivables

14

210,144

110,938

Total current assets

276,061

110,938

 

Current liabilities

Trade and other payables

15

1,586,484

1,487,254

Convertible loan notes

16

2,924,812

-

Total current liabilities

4,511,296

2,075,114

 

Non-current liabilities

Convertible loan notes

16

-

587,860

 

Deferred Tax Liability

793,000

-

Total assets less liabilities

1,204,609

288,016

Capital and reserves

Share capital

18

2,341,110

1,597,031

Share premium

3,468,944

876,347

Share options reserve

32,499

18,788

Retained earnings

(4,637,944)

(2,204,150)

Total equity and liabilities

1,204,609

288,016

 

 

 

Statement of Cash Flows

 

GROUP

 

 

31 Jan 2023

Note

 

£

Cash flows from operating activities

Loss for the year

(1,139,640)

Adjustments for:

Depreciation

172,284

Share based payment expense

13,711

Net finance expense

247,983

Write-off of assets under construction

39,878

Write-off of stocks

7,393

Increase in trade and other receivables

(143,568)

Increase in trade and other payables

344,604

Net cash outflow from operating activities

19

 

(457,354)

 

Investing activities

Cash from acquisition

29,563

Additional investments prior to DJT acquisition

(1,476,598)

 

 

 

Net cash outflow from investing activities

(1,446,944)

Financing activities

Proceeds from loans and borrowings

1,888,845

Repayment of loans and borrowings

(40,000)

Proceeds from issue of ordinary shares

74,290

Net cash inflow from financing activities

 

1,923,135

Net decrease in cash and cash equivalents

18,837

Cash and cash equivalents at beginning of period

-

Cash and cash equivalents at end of year

 

18,837

 

 

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

ANANDA DEVELOPMENTS PLC

+44 (0)7463 686 497

ir@anandadevelopments.com

Chief Executive Officer

Melissa Sturgess

Finance Director

Jeremy Sturgess-Smith

SP ANGEL CORPORATE FINANCE LLP

+44 (0)20 3470 0470

Corporate Finance

Richard Morrison

Harry Davies-Ball

 

Corporate Broking

Abigail Wayne

Rob Rees

 

 

About Ananda Developments

 

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

 

For more information, please visit: https://anandadevelopments.com/

 

Market Abuse Regulation (MAR) Disclosure

 

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXFLFVRDAILVIV
Date   Source Headline
2nd May 202412:00 pmRNSResponse to FSA-FSS Cannabidiol Safety Assessment
21st Mar 20247:00 amRNSEstablishment of Scientific Advisory Board
28th Feb 20247:00 amRNSEndometriosis Trial Drug Supply Agreement Signed
26th Feb 202412:00 pmRNSAnanda presenting at Master Investor Show
26th Feb 20247:00 amRNSQuarterly Trading Statement to 31 January 2024
6th Feb 20247:00 amRNSAppointment of Adviser
23rd Jan 20247:00 amRNSAppointment of Scientific Advisers
14th Dec 20237:00 amRNSAnanda Launches New Interactive Investor Hub
29th Nov 20232:39 pmRNSQuarterly Trading Statement to 31 October 2023
14th Nov 20237:00 amRNSDrug Supply Agreement Signed
8th Nov 20237:30 amRNSInvestor Presentation via Investor Meet Company
8th Nov 20237:00 amRNSTHC Oil Patent Application Filed
1st Nov 20237:00 amRNSMOU signed with Nottingham Trent University
24th Oct 20232:20 pmRNSInterim Results to 31 July 2023
6th Sep 20237:00 amRNSIssue of Convertible Loan Notes
31st Aug 20237:00 amRNSShareholder Update
25th Aug 202312:01 pmRNSResearch Roundup
24th Aug 20232:28 pmRNSResult of AGM
15th Aug 20237:00 amRNSNHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL
31st Jul 20235:44 pmRNSCompletion of Audit & Notice of AGM
27th Jul 20237:00 amRNSFirst Cannabinoid Medicines Launched
13th Jul 202310:22 amRNSUnaudited Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.